Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
November 20, 2018
Revance to Participate in Upcoming Investor Conferences
November 7, 2018
Revance to Participate in the Credit Suisse Healthcare Conference
November 1, 2018
Revance Releases Third Quarter 2018 Results
October 18, 2018
Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
October 11, 2018
Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
September 24, 2018
Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference
September 20, 2018
Revance Receives Great Place to Work Certification
August 2, 2018
Revance Releases Second Quarter 2018 Results
July 19, 2018
Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018
June 21, 2018
Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia
Displaying 131 - 140 of 280